Karyopharm Therapeutics
KPTI
96 hedge funds and large institutions have $207M invested in Karyopharm Therapeutics in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 14 closing their positions.
246% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $3.97M
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
109% more capital inflows, than outflows
Capital inflows: $77.4M | Capital outflows: $37.1M
25% more funds holding
Funds holding: 77 → 96 (+19)
2.95% less ownership
Funds ownership: 96.3% → 93.36% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Acorn Capital Advisors
New York
|
+$10.7M |
| 2 |
BlackRock
New York
|
+$10.2M |
| 3 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$5.95M |
| 4 |
NEA Management Company
Timonium,
Maryland
|
+$5M |
| 5 |
Two Sigma Investments
New York
|
+$4.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commodore Capital
New York
|
-$10.9M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.56M |
| 3 |
Ikarian Capital
Dallas,
Texas
|
-$4.09M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.47M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1.66M |
KPTI Hedge Fund Activity: Q2 2026 in Review
96 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2026, worth a combined $207M — up 110% from $98.4M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new KPTI positions and 14 closed out — a net gain of 19 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was Acorn Capital Advisors, adding an estimated $10.7M. The largest seller was Commodore Capital, exiting entirely with an estimated $10.9M sold.
- 96 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2026, up from 77 in Q1 2026.
- Funds reported $207M of Karyopharm Therapeutics stock for Q2 2026, up 110% quarter-over-quarter.
- 33 funds opened new Karyopharm Therapeutics positions in Q2 2026 and 14 closed out, a net change of +19 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2026 was Acorn Capital Advisors, an estimated $10.7M added.
- The largest Karyopharm Therapeutics seller in Q2 2026 was Commodore Capital, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2026.